Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LBX Pharmacy Chain JSCSHSE:603883 -3.00%80 Return-on-Tangible-Equity is 432.32% as of Mar. 2026, which is 352% above its 10-year median of 95.61. GuruFocus rates SHSE:603883 with a GF Score™ of 80/100 and a GF Value™ of ¥19.25 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 576 Healthcare Providers & Services companies, LBX Pharmacy Chain JSC ranks better than 87.5% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. LBX Pharmacy Chain JSC's annualized net income for the quarter that ended in Mar. 2026 was ¥1,055 Mil. LBX Pharmacy Chain JSC's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥244 Mil. Therefore, LBX Pharmacy Chain JSC's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 432.32%.
The historical rank and industry rank for LBX Pharmacy Chain JSC's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:603883'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 33.25 Med: 95.61 Max: 1025.02
Current: 199.83
During the past 13 years, LBX Pharmacy Chain JSC's highest Return-on-Tangible-Equity was 1,025.02%. The lowest was 33.25%. And the median was 95.61%.
SHSE:603883's Return-on-Tangible-Equity is ranked better than 87.5% of 576
companies
in the Healthcare Providers & Services industry
Industry Median: 10.17
vs SHSE:603883: 199.83
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
LBX Pharmacy Chain JSC Return-on-Tangible-Equity Related Terms
LBX Pharmacy Chain JSC Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for LBX Pharmacy Chain JSC's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, LBX Pharmacy Chain JSC's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LBX Pharmacy Chain JSC Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, LBX Pharmacy Chain JSC's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where LBX Pharmacy Chain JSC's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 432.32% mean?
LBX Pharmacy Chain JSC (SHSE:603883) has a Return-on-Tangible-Equity of 432.32% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on LBX Pharmacy Chain JSC and its competitors. This is 352% above median its historical median of 95.61. Over the past decade, LBX Pharmacy Chain JSC's Return-on-Tangible-Equity has ranged from 33.25 to 1,025.02. According to the industry distribution chart, LBX Pharmacy Chain JSC ranks #72 out of 576 companies in the Healthcare Providers & Services industry, placing it in the top 12.5%.
Is LBX Pharmacy Chain JSC's Return-on-Tangible-Equity too high?
LBX Pharmacy Chain JSC's current Return-on-Tangible-Equity of 432.32% is 352% above median its 10-year median of 95.61. Over the past 10 years, this metric has ranged from a low of 33.25 to a high of 1,025.02. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.17. LBX Pharmacy Chain JSC's value of 432.32% is 4150.9% above this industry median. Based on the distribution chart, LBX Pharmacy Chain JSC ranks #72 out of 576 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, LBX Pharmacy Chain JSC has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LBX Pharmacy Chain JSC's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, LBX Pharmacy Chain JSC ranks #72 out of 576 companies for Return-on-Tangible-Equity. This places LBX Pharmacy Chain JSC in the top 13% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.17. LBX Pharmacy Chain JSC's value of 432.32% is 4150.9% above this benchmark. Historically, LBX Pharmacy Chain JSC's own Return-on-Tangible-Equity has ranged from 33.25 to 1,025.02 over the past decade. While the company's 10-year median is 95.61 vs. the industry median of 10.17, LBX Pharmacy Chain JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.17, based on 576 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LBX Pharmacy Chain JSC's current Return-on-Tangible-Equity of 432.32% is 4150.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on LBX Pharmacy Chain JSC and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LBX Pharmacy Chain JSC's current Return-on-Tangible-Equity is 432.32%, which is 352% above median its own 10-year median of 95.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LBX Pharmacy Chain JSC stock overvalued right now?
Based on GuruFocus' analysis, LBX Pharmacy Chain JSC (SHSE:603883) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥19.25, compared to a current price of ¥11.97 — trading 37.8% below its estimated fair value. The current Return-on-Tangible-Equity is 432.32%, which is 352% above median its 10-year median of 95.61 and 4150.9% above the Healthcare Providers & Services industry median of 10.17. LBX Pharmacy Chain JSC's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For LBX Pharmacy Chain JSC (SHSE:603883), the current Return-on-Tangible-Equity is 432.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LBX Pharmacy Chain JSC (SHSE:603883) Overvalued in 2026?
Based on GuruFocus' analysis, LBX Pharmacy Chain JSC stock appears to be undervalued.
The current stock price of ¥11.97 is trading 37.8% below its estimated GF Value™ of ¥19.25.
GuruFocus considers LBX Pharmacy Chain JSC to be Significantly Undervalued.
Key valuation signals for SHSE:603883:
Return-on-Tangible-Equity: 432.32% (352% above median its 10-year median of 95.61)
GF Value™: ¥19.25 vs. price of ¥11.97 (37.8% below fair value)
Industry Position: 4150.9% above the Healthcare Providers & Services median (#72 of 576)
No single metric tells the full story. See the SHSE:603883 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LBX Pharmacy Chain JSC is a China-based company engages in the sale of medicine and health products. The company is engaged in retailing drugs and other related products, including Chinese and Western medicine, prepared slices of Chinese crude drugs, health equipment, healthy food, and personal care products and life care products. The company is also involved in the wholesale and manufacture of drugs.
80GF Score
Get the complete analysis for SHSE:603883
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603883 has been successfully added to your 
